NCT02401945已完成2 期
A Multicenter, Randomized, Open Label, Phase IIa Study Assessing the Efficacy, Safety and Duration of Effect of Intravitreal Injections of DE-120 as Monotherapy and With a Single Eylea® Injection in Subjects With Treatment-Naive Exudative Age-Related Macular Degeneration
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Santen Inc.
- 入组人数
- 16
- 主要终点
- Mean change from baseline in BCVA at Month 8
研究概览
简要总结
The purpose of the study is to evaluate the safety and efficacy of intravitreal (IVT) administration of DE-120 in subjects with treatment-naive active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide signed written informed consent
- •Diagnosis of active CNV secondary to wet AMD, with some subfoveal component in the study eye
- •No evidence of subfoveal fibrosis or subfoveal RPE atrophy in the study eye
- •At least one lesion in the study eye that meets minimal pathology criteria
- •Best corrected visual acuity of 70 to 25 ETDRS letters in the study eye
- •Best corrected visual acuity of 20/320 or better in the fellow eye
- •Reasonably clear media and some fixation in the study eye
排除标准
- •Aphakic or has an anterior chamber intraocular lens in the study eye
- •Received prior treatment with anti-VEGF, intravitreal corticosteroids or photodynamic therapy in the study eye
- •Uncontrolled glaucoma despite anti-glaucoma therapy in the study eye
- •Evidence of any ocular disease other than AMD in the study eye that may confound the outcome of the study
- •History of vitrectomy in the study eye
- •Need for ocular surgery in the study eye during the course of the trial
- •Presence or history of certain ocular or periocular pathology or conditions that could limit ability to perform required study assessments in either eye and/or confound study results
- •Allergy or hypersensitivity to study drug product, fluorescein dye or other study-related procedures and medications
- •Current or history of certain systemic conditions, abnormalities or therapies that would render a subject a poor candidate for the study
- •Participation in other investigational drug or device clinical trials within 30 days prior to randomization or planning to participate in other investigational drug or device clinical trials for the duration of the study
- •Females who are pregnant or lactating and females of child-bearing potential who are not using adequate contraceptive precautions and men who do not agree to practice an acceptable method of contraception throughout the course of the study
- •Unable to comply with study procedures or follow-up visits
研究组 & 干预措施
DE-120 Monotherapy
Experimental
DE-120 intravitreal injection given as monotherapy on a PRN basis
干预措施: DE-120 (Drug)
Eylea® and DE-120 Concomitant Therapy
Experimental
DE-120 intravitreal injection given on a PRN basis after Aflibercept (Eylea®) injection as an induction therapy.
干预措施: DE-120 (Drug)
Eylea® and DE-120 Concomitant Therapy
Experimental
DE-120 intravitreal injection given on a PRN basis after Aflibercept (Eylea®) injection as an induction therapy.
干预措施: Aflibercept (Drug)
结局指标
主要结局
Mean change from baseline in BCVA at Month 8
时间窗: Month 8
次要结局
- Change from baseline in greatest linear dimension of the area of leakage at Month 8(Month 8)
- Change from baseline in total lesion area at Month 8(Month 8)
- Change in Central Subfield Thickness at Month 8(Month 8)
研究者
相似试验
招募中
2 期
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMDGeographic Atrophy (GA)Age - Related Macular Degeneration (AMD)NCT06659445ONL Therapeutics324
终止
3 期
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyAge-Related Macular DegenerationNCT01940900Ophthotech Corporation627
终止
3 期
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyAge-Related Macular DegenerationNCT01944839Ophthotech Corporation619
终止
3 期
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® MonotherapyAge-Related Macular DegenerationNCT01940887Ophthotech Corporation645
已完成
2 期
Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic RetinopathyHigh Risk Proliferative Diabetic RetinopathyNCT01280929José Cunha-Vaz54